Sulopenem is a thiolanylthiopenem derivative patented by American multinational pharmaceutical corporation Pfizer Inc as an antibiotic with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem showed concentration-dependent bactericidal activities against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter calcoaceticus. Morphological observation using a phase-contrast microscope revealed that sulopenem induced spherical cell formation with E. coli and K. pneumoniae at lower concentrations and bacteriolysis at higher concentrations. Therapeutic efficacies of sulopenem against systemic infections in mice were almost equal to those of imipenem against Streptococcus pneumoniae.

Tiazuril is a triazinedione derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as the coccidiostatic agent. Tiazuril controlled all the major species of poultry coccidia at low concentrations but elicited toxicological symptoms suggesting interference with nucleic acid synthesis.

Terlakiren (also known as CP80794) is a cysteinamide derivative patented by Pfizer Inc. as potent renin inhibitor. Terlakirens inhibitory potency against plasma renin of guinea pigs, dogs, and monkeys ranges from 0.3 to 0.7 nM. In preclinical models, Terlakiren caused significantly greater increases in renal blood flow and suppressed renin activity to a greater degree than captopril.

FLUMIZOLE, a substituted diarylimidazole, is a weak acidic, nonsteroidal, anti-inflammatory agent. It is a potent cyclooxygenase inhibitor. FLUMIZOLE is severalfold more potent than indomethacin and 470 times more active than phenylbutazone in a system examining prostaglandin production.

Propikacin (also known as UK31214) is kanamycin B derivative patented by Pfizer Inc. as antibacterial compound. In preclinical studies Propikacin shows antibacterial activity against the Enterobacteriaceae, P. stuartii strains and the gentamicin-resistant strains of P. aeruginosa.

Sudoxicam is a nonsteroidal anti-inflammatory drug patented by American multinational pharmaceutical corporation Pfizer for the treatment of thrombosis. Sudoxicam strongly inhibited aggregation of rabbit, dog, and human platelets caused by collagen, but not by ADP. Sudoxicam inhibited the secondary phase of the biphasic response of guinea pig platelets to ADP and suppressed the release of ADP from human platelets caused by collagen. Sudoxicam shows superior anti-inflammatory activity compare to indomethacin in rat paw edema model. In clinical trials, sudoxicam was associated with several cases of severe hepatotoxicity that led to its discontinuation.

Tibric Acid is a sulfamoylbenzoic acid derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as a hypolipidemic agent. In preclinical models, Tibric acid, given orally, was more effective than clofibrate in preventing the hyperlipemic and hypercholesteremic effects of various diets in rats. At high concentrations in vitro, Tibric acid moderately inhibited ADP- or thrombin-induced aggregation of rabbit blood platelets. In patients with severe type IV hyperlipoproteinemia and chylomicronemia, Tibric Acid lowered serum triglyceride and cholesterol values but administration of Tibric Acid to a normal subject did not affect serum lipid levels.

HYDROXYDIONE is a neuroactive steroid used formerly as a general anesthetic. It was discontinued due to a high incidence of post-anesthetic thrombophlebitis, delayed onset of anesthesia and an unacceptably long duration of action.

Sulopenem is a thiolanylthiopenem derivative patented by American multinational pharmaceutical corporation Pfizer Inc as an antibiotic with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem showed concentration-dependent bactericidal activities against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter calcoaceticus. Morphological observation using a phase-contrast microscope revealed that sulopenem induced spherical cell formation with E. coli and K. pneumoniae at lower concentrations and bacteriolysis at higher concentrations. Therapeutic efficacies of sulopenem against systemic infections in mice were almost equal to those of imipenem against Streptococcus pneumoniae.

Sulopenem is a thiolanylthiopenem derivative patented by American multinational pharmaceutical corporation Pfizer Inc as an antibiotic with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem showed concentration-dependent bactericidal activities against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter calcoaceticus. Morphological observation using a phase-contrast microscope revealed that sulopenem induced spherical cell formation with E. coli and K. pneumoniae at lower concentrations and bacteriolysis at higher concentrations. Therapeutic efficacies of sulopenem against systemic infections in mice were almost equal to those of imipenem against Streptococcus pneumoniae.